financetom
Business
financetom
/
Business
/
Ulta Beauty Q2 Results Fueled By Growth Across All Major Categories, Beauty Retailer Beats Revenue, EPS Estimates, Raises Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ulta Beauty Q2 Results Fueled By Growth Across All Major Categories, Beauty Retailer Beats Revenue, EPS Estimates, Raises Guidance
Aug 28, 2025 2:16 PM

Ulta Beauty Inc ( ULTA ) reported financial results for the second quarter after the market close on Thursday. Here’s a rundown of the specialty beauty retailer’s report.

ULTA is poised for a potential breakout. Track the latest developments here.

Q2 Highlights: Ulta Beauty ( ULTA ) reported second-quarter revenue of $2.79 billion, beating the consensus estimate of $2.67 billion. The company reported second-quarter earnings of $5.78 per share, beating analyst estimates of $4.97 per share, according to Benzinga Pro.

Total revenue was up 9.3% year-over-year in the second quarter. Comparable sales were up 6.7% year-over-year, driven by a 3.7% increase in transactions and a 2.9% increase in average ticket.

“Outstanding top line performance, fueled by growth across all major categories, drove market share growth and better-than-expected profitability,” said Kecia Steelman, president and CEO of Ulta Beauty ( ULTA ).

Ulta said it added 24 new stores in the quarter and closed two, bringing total locations up to 1,473. Merchandise inventories were up 20.5% year-over-year to $2.4 billion. The company ended the quarter with $242.7 million in cash and cash equivalents.

Outlook: Ulta Beauty ( ULTA ) raised its fiscal year 2025 revenue from a range of $11.5 billion to $11.7 billion to a new range of $12 billion to $12.1 billion versus estimates of $11.69 billion. The company also raised its full-year earnings forecast from a range of $22.65 to $23.20 per share to a new range of $23.85 to $24.30 per share versus estimates of $23.58 per share.

Ulta Beauty ( ULTA ) said it now expects full-year comparable sales growth of 2.5% to 3.5%, up from prior guidance of flat to up 1.5%.

“Our outlook for the remainder of the year reflects both the strength of our year-to-date performance and our caution around how consumer demand may evolve in the second half of the year,” Steelman said.

Ulta Beauty ( ULTA ) executives will further discuss the quarter on an earnings call with investors and analysts at 4:30 p.m. ET.

ULTA Price Action: Ulta Beauty ( ULTA ) shares were up 5.57% in after-hours Thursday, trading at $560.17 at the time of publication, according to Benzinga Pro.

Read Next:

S&P 500 Breaks New Records But Nvidia Misses The Party: What’s Moving Markets Thursday?

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Marinus Pharmaceuticals Ztalmy Gains Approval From UK Medicines and Healthcare Products Regulatory Agency
Marinus Pharmaceuticals Ztalmy Gains Approval From UK Medicines and Healthcare Products Regulatory Agency
Mar 7, 2024
01:25 PM EST, 03/07/2024 (MT Newswires) -- Marinus Pharmaceuticals' ( MRNS ) Ztalmy was approved by the UK Medicines and Healthcare products Regulatory Agency on Thursday for the treatment of seizures in patients with cyclin-dependent kinase-like 5 deficiency disorder. Ztalmy, or ganaxolone, is the first anti-seizure medication approved for the treatment of this rare genetic disorder in the UK, according...
3M, HD Hyundai Korea Shipbuilding & Marine Engineering to Partner on Research for Liquid Hydrogen Storage Tanks
3M, HD Hyundai Korea Shipbuilding & Marine Engineering to Partner on Research for Liquid Hydrogen Storage Tanks
Mar 7, 2024
01:20 PM EST, 03/07/2024 (MT Newswires) -- 3M ( MMM ) agreed with HD Hyundai Korea Shipbuilding & Marine Engineering on a joint research project to develop large liquid hydrogen storage tanks using the conglomerate's glass bubbles insulation system. This collaboration is a major step forward in the pursuit of making hydrogen technologies available at scale, 3M Advanced Materials Division...
Cellebrite Launches FedRAMP Authorization Process for SaaS Offerings
Cellebrite Launches FedRAMP Authorization Process for SaaS Offerings
Mar 7, 2024
01:20 PM EST, 03/07/2024 (MT Newswires) -- Cellebrite DI ( CLBT ) said Thursday it has launched the process to seek Federal Risk and Authorization Management Program, or FedRAMP, authorization for its software-as-a-service offerings. The company said it has enlisted cybersecurity firm Coalfire to assist in the activities required to complete the process within the next 12 months. FedRAMP authorization...
Why Is Diabetes Focused Creative Medical Stock Surging On Thursday?
Why Is Diabetes Focused Creative Medical Stock Surging On Thursday?
Mar 7, 2024
Thursday, Creative Medical Technology Holdings Inc ( CELZ ) secured FDA authorization for an expanded access therapy using CELZ-201, a cell-based program to manage abnormal glucose tolerance and prevent Type 1 diabetes (T1D) in high-risk individuals. The therapy uses CELZ-201 to potentially prevent T1D onset and is believed to be a first in medical history.  This personalized medicine approach focuses on a single...
Copyright 2023-2026 - www.financetom.com All Rights Reserved